MRK•benzinga•
Merck shares are trading higher after the company reported topline results from its pivotal Phase 3 MK-3475A-D77 trial, which met its dual primary pharmacokinetic endpoints.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga